APR 11 2008 (S)		
FORM PTO-1449 (2)	SERIAL NO.	CASE NO.
Et a mouldit	09/902,572	10466/77
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	July 10, 2001	1642
STATEMENT		
(use several sheets if necessary)	APPLICANT(S): Ashkenazi et al	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
				750	-1\/ED
				REC	SIVED
				APR 1	2 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS			IEUA CENTETT TOOGESTE		
DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSI YES	LATION NO
		· · · · · · · · · · · · · · · · · · ·			
	<del> </del>				
<del></del>	+	<del></del>			
	+		-		
	DOCUMENT	DOCUMENT	DOCUMENT	DOCUMENT CLASS/	DOCUMENT CLASS/ TRANSI

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
TAL	A1	Blast Results A1-A21, GenBank
AND	A2	Blast Results, B1-B6, Dayhoff

EXAMINER /	. /	DATE CONSIDERED	
Swedd & he	//-/.	11/17/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Rev. Dcc.-99



SHEET 5 of 5

	TRADEM		SHEEL JOLJ
INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	SERIAL NO.
		39780-1618P2C40	09/902,572
PTO-1449		APPLICANT Ashkenazi et al	•
		FILING DATE: 07/10/01	GROUP: 1636
	OTHER DOCUMENTS	Including Author, Title, Date, Pertin	ent Pages, Etc.)
AAA	Collins, et al; "Characterization factor in vivo", Br. J. Pharmac	on of the increase in vascular permeabil col. (1993), 109, 195-199.	ity induced by vascular permeability
ADD.		ue fluorimetry for determination of pul fluid resuscitation of burn shock", Burn	
ADJ.		lial growth factor (VEGF)-like protein Acad. Sci., USA, Vol. 96, pp. 3071-30	
· ·			BEOD
	LECEIVED		
			JUN 0 2 2000
}			TECH CEARL
	JUN 0 2 2003 TECH CENTER 1600/2900		
1			
	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
			<del></del>
<b>(</b>			
		<u> </u>	
<b>(</b>			
ļ		. <del></del>	
			<del></del>
EXAMINER 6	weald to helf of	DATE CONSIDERED 11/1	2/03
	V		



ATTY. DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE TON O 2 TOWN OF THE WAY THE WA **STATEMENT** 39780-1618P2C40 09/902,572 APPLICANT Ashkenazi et al. PTO-1449 GROUP: 167 FILING DATE: 07/10/01 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Cho et al; "Cloring of novel serine carboxypeptidase precursor" Direct submission to Microbiolo Hee University, Hoeki 1, Seoul, Korea; RISC HUMAN; Submitted 26 June, 2000, Komatsoulis et al; "Isolated nucleic acid-molecules encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition," P\_AAU96225; WO200224721-A1; Filing: 9 Jan, 2001; Publication date: 28 March 2002. Shimkets et al; "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease," P\_AAB41675, WO200058473-A2, Filing: 31 March 1999; Publication date: 05 October 2000. Liu et al; Direct submission to Molecular Medical Center for Cardiovascular Disease, Cardiovascular Institute, CAMS AND PUMC; 167, Bei Li Shi Lu, Beijing 180037, P.R. China; AAG39285.1; Accession No: AFT13214; submitted 15 December 1998. Chen et al; "Clouing of a novel retinoid-indusible serine carboxypertidase from vascular smooth muscle cells," J. Biol. Chem. 276 (36), 34175-34181 (2001); NP 067639. Baker et al; "One hundred and eighty seven nucleic acids encoding RRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammall, P ABB84842; WO200200690-A2, Pat 19 Jul, 2002, Filing: July 9, 2001; Publication Date: Japuary 3, 2002. Baker et al: "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal, P\_ABB95448; WO200208284-A2, Pat 19 Jul, 2002, Filing: July 9, 2001; Publication Date: January 31, 2002. White et al; "Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the transcriptome/ proteome of two cell types under different conditions and identifying a differentially regulated gene" P\_ABP65102; WO200246465-A2; Rublication Date: 13 June 2002; Pat 12 Nov, 2002. Miano et al; "New retinoid-inducible serine carboxypeptidaee proteins and nucleic acids, useful for detecting or treating vascular diseases, e.g. vascular hyperplasia, atheresclerosis, asthma, glomerulonephritis, hypertension" P ABB99213; WO200268599-A2, Publication date: 06 September 2002 Pat 29 Nov, 2002. Ashkenazi et al; "Sixty one nuleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases, cancers and neurodegenerative diseases", P. AAB80255; WO200104311-A1 Pat 24 Apr, 2001, Filed: February 22, 2000, Publication date: 18 January 2001. **EXAMINER** DATE CONSIDERED



SHEET 1 OF 5

The state of the s		SHEET LOF 3	
INFORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.	
STATEMENT	39780-1618P2C40	09/902,572	
PTO-1449	APPLICANT Ashkenazi et al.		
	FILING DATE: 07/10/01	GROUP: 1736 2 2003	
OTHER DOCUMENTS (	Including Author, Title, Date, Pertine	ent Pages, Etc.)	
promoting or inhibiting angiog	prising a PRO230, PRO216 or PRO302 genesis and/or cardiovascularisation in r y, <del>2001, filed:</del> November 29, 1999		
useful for promotion or inhibit	composition comprising PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists motion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals", y WO200015792-A2, Pat 20 July 2000, filed: September 13, 1999.		
Chen, et al; "New isolated hum ulceration", P_AAX52258; W	nan genes and polypeptides used in, e.g 09914328-A2, Pat 25 June 1998, filed:	treatment of gastrointestinal September 16, 1998.	
	Fong et al: "Composition comprising human polypeptides with anti-angiogenic activity", P_AAX25445; WO9914234-A2; Pat 19 July 1999, filed: September 14, 1998.		
	leic acids encoding PRO polypeptides vodegenerative diseases", P_AAF72416		
	eighty seven nucleic acids encoding PR r, endothelial or angiogenic disorders in y 2002, Filing: July 9, 2001.		
	eighty seven mucleic acids encoding PR r, endothelial or angiogenic disorders in y 2002, Filing: June 20, 2001.		
	Fong et al; "Promotion of inhibition of angiogenesis and cardiovascularization," AX098272; WO0119987-A11, Pat 2 Apr. 2001, Pub: Mar. 22, 2001.		
Baker et al; "Copposition and ongiogenesis" AX454466; WO	Baker et al; "Composition and methods for the diagnosis and treatment of disorders involving angiogenesis" AX454466; WO0208284-A 51; Pat 6 July 2002, Pub: Jan 31, 2002.		
	Wood et al; "Secretory and transmembrane polypeptide and nucleic acre encoding the same" BD075577; JP2001516580-A 210; Pat 27 Aug. 2002, Oct 2, 2001.		
Wood et al; "Secretory and fran JP2002238588-A 210; Pat 18 F	Wood et al; "Secretory and transmembrane polypoptide and nucleic acid encoding the same" BD173394; JP2002238588-A 210, Pat 18 Feb. 2003.		
	Wood et al; "Sestetory and transmembrane polypeptide and nucleic acid encoding the same" BD173075; JP2002238587-A 219; Pat 18 Feb. 2003.		
Baker et al; "Composition and angiogenesis" AX490944; WO	Baker et al; "Composition and methods for the diagnosis and treatment of disorders involving angiogenesis" AX490944; WO0200690-A51; Pat 16 Aug. 2002.		
Wand et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD172756; JP2002238586-A 210; Par 18 Feb. 2003.			
EXAMINER Second to hel.	DATE CONSIDERED 11/17/	/03	



SHEET 2 OF 5

SHEET 2 OF			21 Z OF 3	
INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	SERIAL NO.	
		39780-1618P2C40	09/902,572	
РТО-1449		APPLICANT Ashkenazi et al		PECE
		FILING DATE: 07/10/01	GROUP: 1636	PECE JUN 0 2 200
OTHER	DOCUMENTS	(Including Author, Title, Date, Pertin	ent Pages, Etc.)	CEAN 200
Wood et al: IP200272378	Secretory and tr 86-A 210; Pat 18	APPLICANT Ashkenazi et al.  FILING DATE: 07/10/01  (Including Author, Title, Date, Pertin ansmembrane polypeptide and nucleic a Feb, 2003.  ansmembrane polypeptide and nucleic a	cid encoding the same	BD (1233)
Wood et al; 1 JP200225328	Secretory and tr 30-A 210; Pat 18	ansmembrane polypeptide and nucleic a Mar, 2003.	cid encoding the same	BD175428;
detecting or	reating vascular	ducible serine carboxypeptidase protein diseases, e.g. vascular hyperplasia, atho- ion" P_ABV72656; WO200268599-A2	rosclerosis, asthma	eful for
comparing th	White et al; "Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the transcriptome/ proteome of two cell-types under different conditions and identifying a differentially regulated gene P_ABV77921; WO200246465-A2, Pat 12 Nov, 2002.			
Cho et al; "C Kyun <del>g Hee</del> C	Cho et al; "Cloning of novel serine carboxypeptidase precursor" Direct submission to Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea; AF282618; Submitted 26 June, 2000, Priority 27 Sep, 2000.			
Chen et al; "C	Chen et al; "Cloping of a novel retinoid-inducible serine sarboxypeptidase from vascular smooth muscle cells" NM 021626; J. Biol. Chem. 276 (36), 34175-181 (2001).			
the specificat	Ota et al; "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs" P_AAH15579: EP1074617-A2, Pat 26 June, 2001.			
correlating w	Schlegel et al; "Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer" P_ABV28721; WO200160860-A2; Pat 16 Sep, 2002.			
Isogai et al; L Chiba 292-08	Isogai et al; Direct submission to Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan; AK027373; submitted 10 May, 2001.			
Ota et al; "Pri Pat 17 Jan, 20		zing full-length cDNA and use thereof	ВD157571; JP 200219	91363-A12414;
	Schleger et al; "New isolated nucleic acid for diagnosing and treating cervical cancer and for assessing and detecting compounds for treating the cancer"; P_AAH72787; WO200142467-A2; at 19 Sep, 2001.			
	Schlegel et al; "Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of servical cancer"; AX188369; WO0142467-A 4064; Pat 6 Aug, 2001.			
preventing dia	Kate et al; "Human proteins with hydrophobic domains and the nucleis acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation"; P_AAD12590; WO200149728-A2; Par 25 Sep, 2001.			
Kato et al; "H WO0149728-	Kato et al; "Human proteins having hydrophobic domains and DNAs encoding these proteins"; AX191563; WO0149728-A85; Pat 15 Aug, 2001.			s"; AX191563;
EXAMINER Single	Dunk	DATE CONSIDERED 11/17	103	



SHEET 3 OF 5

FOADEMAN		SHEET 3 OF 5	
INFORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.	
STATEMENT	39780-1618P2C40	09/902,572	
PTO-1449	APPLICANT Ashkenazi et al	MECK	
	FILING DATE: 07/10/01	GROUP: 1686 JUN 0	
OTHER DOCUMENTS	(Including Author, Title, Date, Pertin	ent Pages, Etc.)	
Liu et al; Direct submission Institute, 167, Bei Li Shi Lu,	to Molecular Medical Center for Cardio Beijing 100037, P.R. China: AF113214	SERIAL NO.  09/902,572  GROUP: 1636  ent Pages, Etc.)  vascular Disease, Cardiovascalar of the submitted 15 Dec, 1998.  reading frame X useful for treating	
	orders, neurodegenerative disorders and cardiovascular discase,		
family, useful in identifying	acleotides encoding protease homologs of agonists and antagonists for diagnosis ar \$6331427-B1, Pat 23 Apr, 2002.	of the G-protein-coupled protease and treatment of protease mediated	
Ford et al; "Novel bone-marr and immune deficiency disor	ow-expressed polynucleotides and polynders," P. AAH89926; WO200153453-A	peptides, useful for treating e.g. cancer 2; Pat 1 Oct, 2001.	
	Kato et al; "Human proteins having hydrophobic domains and DNAs encoding these proteins," AX191553; W00149728-A75; Pat 15 Aug, 2001.		
promoting or inhibiting angio	Fong et al; "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist for promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals", P_AAB20341; WO200119987-A1, Pat 29 May, 2001, filed: November 29, 1999; Publication date: 22 March 2001.		
the specification, and for the	thesizing polynucleotides, particularly the detection and/or diagnosis of the abnorm 13913; EP1074617-A2; Pat 26 June, 200	nality of the proteins encoded by the	
preventing diagnosing and tre	with hydrophobic domains and the nucle cating e.g. cancer, Alzheimer's and inflates, 2001; Publication date: 12 July 2001	mmation"; P_AAE06395;	
useful for promotion or inhib	nprising a PRO230, PRO216 or PRO302 ption of cordiovascularisation, angiogene 22-A2, filed September 13, 1999; Public	sis or endothelialisation in mammals",	
Chen, et al; "New isolated hu ulceration", P_AAX13387; W 25 March 1999.	man genes and polypeptides used in, e.g. 109914328-A2, Pat 25 Jun, 1999, filed:	treatment of gastrointestinal September 16, 1998; Publication date:	
	Fong et al; "Composition containing human potypeptides with anti-angiogenic activity", R AAY05768; WO9914234-A2; filed: September 14, 1998; Publication date: 25 March 1999.		
Kato et al; unnamed protein p	Kato et al; unnamed protein product; CAC51169.1; WO0149728-A85; 12 Jul, 2001; Publication date:		
Cho et al; Direct submission AAG166921; Submitted 26 J	Cho et al; Direct submission to Microbiology, Kyung Hee University, Hoekid, Seoul, Korca; AAG166921; Submitted 26 June, 2000.		
	Isogai et al; Direct submission to Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan; BAB55069.1; submitted 10 May, 2001.		
EXAMINER Swald & helph L	DATE CONSIDERED 11/17/	103	